Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Caicun Zhou, Ziping Wang, Meili Sun, Lejie Cao, Zhiyong Ma, Rong Wu, Yan Yu, Wenxiu Yao, Si Sun, Jianhua Chen, Wu Zhuang, Jiuwei Cui, Xueqin Chen, You Lü, Hong Shen, Chunhong Hu, Jiwei Liu, Yunpeng Liu, Mengzhao Wang, Xingya Li, Ping Sun, Yongqian Shu, Jianying Zhou, Jingzhang Li, Kangsheng Gu, Changli Wang, Hui Zhao, Yiping Zhang, Chunling Liu, Jingru Wang, Rumei Chen, Mengmeng Qin, Hao Wang, Jason YangNature Cancer 2024 · DOI · OpenAlex

Introduction

The GEMSTONE-302 trial represents a significant milestone in the treatment of metastatic non-small-cell lung cancer (NSCLC), evaluating the efficacy of the anti-PD-L1 monoclonal antibody sugemalimab. However, the initial publication of the interim survival analysis in June 2023 omitted several foundational documents essential for full scientific transparency. This publisher correction addresses those omissions, providing the clinical trial protocol, statistical analysis plan (SAP), and the CONSORT checklist.

Addressing the Transparency Gap

In high-impact clinical research, the "results" are only as reliable as the "process." The original publication of the GEMSTONE-302 results lacked the supplementary blueprints—the protocol and SAP—that allow the broader scientific community to verify the study's integrity. Without these documents, external researchers cannot fully confirm that the trial was executed as planned or that the statistical methods were not adjusted post-hoc to favor specific outcomes.

By restoring these documents to the Supplementary Information, this correction ensures that the trial meets the rigorous standards of accountability required for phase III clinical data. This move is essential for preventing practices such as "p-hacking" or data dredging, which can undermine the credibility of clinical findings.

Methodological Context: The GEMSTONE-302 Trial

GEMSTONE-302 is a randomized, double-blind, phase III trial comparing sugemalimab plus chemotherapy against placebo plus chemotherapy as a first-line treatment for metastatic NSCLC. While the clinical findings regarding the efficacy of sugemalimab remain unchanged by this correction, the introduction of the following frameworks is vital for technical scrutiny:

  • Clinical Trial Protocol: Provides the comprehensive operational plan for the study, detailing how the trial was conducted from inception to completion.
  • Statistical Analysis Plan (SAP): Details the pre-defined roadmap for data analysis, ensuring that primary and secondary endpoints were evaluated without bias. This is particularly important for an interim analysis, as it outlines the pre-specified "stopping rules" or "efficacy boundaries" used to determine statistical significance.
  • CONSORT Checklist: A standardized reporting tool that confirms the authors have provided all necessary details regarding trial design, analysis, and interpretation, allowing for quick assessment of internal validity.

Significance for Open Science

The inclusion of these documents facilitates "Open Science" by allowing for independent verification and meta-analysis. For clinicians and researchers, the availability of the SAP and protocol allows for a deeper dive into the granular details of the trial's design. This transparency is crucial for researchers looking to combine GEMSTONE-302 data with other global trials of PD-L1 inhibitors in systematic reviews.

Conclusion

This administrative update does not alter the clinical conclusions of the GEMSTONE-302 trial; the efficacy of sugemalimab in metastatic NSCLC remains supported by the data. However, the correction is a necessary step in maintaining the integrity of the peer-reviewed record. It ensures that the "blueprints" of the study are accessible for technical scrutiny, reinforcing the trial's contribution to the field of oncology through a transparent and reproducible methodological framework.

Summary updated

BibTeX
@inproceedings{zhou2024publisher,
  author = {Caicun Zhou and Ziping Wang and Meili Sun and Lejie Cao and Zhiyong Ma and Rong Wu and Yan Yu and Wenxiu Yao and Si Sun and Jianhua Chen and Wu Zhuang and Jiuwei Cui and Xueqin Chen and You Lü and Hong Shen and Chunhong Hu and Jiwei Liu and Yunpeng Liu and Mengzhao Wang and Xingya Li and Ping Sun and Yongqian Shu and Jianying Zhou and Jingzhang Li and Kangsheng Gu and Changli Wang and Hui Zhao and Yiping Zhang and Chunling Liu and Jingru Wang and Rumei Chen and Mengmeng Qin and Hao Wang and Jason Yang},
  title = {{Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC}},
  booktitle = {Nature Cancer},
  year = {2024},
  doi = {10.1038/s43018-023-00719-4},
}
Figure